Testing a T Cell Treatment for People With Glioblastoma
Original title: CARv3-TEAM-E T Cells in Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find the right dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a treatment made from a person's own immune cells in people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
Who this trial is for. This trial is for people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, a kind of brain tumor. It is testing a treatment called CARv3-TEAM-E T Cells. These are T cells, a type of immune cell, taken from the person's own body.
Where it stands. The trial has not reported results. The team is trying to find the best dose of these T cells. That answer is not in yet.
What this means, and what it doesn't
What it could mean: If you have glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, this is one study you could ask your care team about. They can help you think through whether it fits your situation. Whether anyone can join is decided by the trial team.
What it doesn't mean: This does not mean the treatment is proven. A trial is a test, not a treatment you can count on. Being in a trial is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.